SLNO (Soleno Therapeutics Corp) Earnings growth in current year

SLNO (Soleno Therapeutics Corp) - company brandmark

Soleno Therapeutics (SLNO) EPS growth compared to the same period last year is based on the development of orphan drugs and patent protection. The focus on Prader-Willi syndrome reduces competition, while the success of clinical trials strengthens physician confidence. Meanwhile, the 1003.50 mark serves as a current indicator that integrates real profit growth with investor market expectations.

SLNO: Soleno Therapeutics Earnings per share growth in current year 07/04/2022 - 05/30/2026

Financial and market metric breakdowns for Soleno Therapeutics Inc (SLNO)

- share price and expert price forecast:
Basic company analysis:SLNO - Soleno Therapeutics Corp
Finished products of Soleno Therapeutics, Inc.

The commercialization of Prader-Willi syndrome therapy defines the potential of Soleno Therapeutics (SLNO), transforming scientific developments into tangible financial results. This indicator measures the annual dynamics of net income per share, allowing investors to assess capital management efficiency and business scaling rates via the relative EPS YoY trend, which is critical for analyzing the sustainability of a biopharmaceutical startup.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|FOLD: Earnings growth in current year|ETNB - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year